Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review and expert commentary with no new human data.
PubMed 39400117 · doi:10.1210/clinem/dgae722
What was done
This is a narrative clinical review examining the relationship between glucagon-like peptide 1 receptor agonists (GLP1RAs) and thyroid malignancies. The authors summarize existing preclinical and clinical evidence concerning medullary thyroid carcinoma and differentiated thyroid cancer, and use clinical cases to discuss management, screening, and evaluation strategies.
What was found
The abstract reports no numerical findings. It notes that while GLP1RA use is contraindicated in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 based on rodent studies, clinical evidence regarding differentiated thyroid cancer risk is conflicting across studies. Consequently, no clear clinical consensus exists for screening prior to initiating treatment or evaluating for thyroid cancer during therapy.
Why it matters
With the rapid expansion of GLP-1 receptor agonist use for diabetes and obesity, clinicians need guidance on managing thyroid nodules and assessing thyroid malignancy risks despite contradictory evidence.
Limits
The paper is a non-systematic narrative review providing expert commentary rather than primary human data or pooled meta-analytic estimates. Available clinical evidence on differentiated thyroid cancer risk remains observational and inconsistent.
Cited by
- supports GLP-1 receptor agonist medications carry an FDA black box warning for thyroid cancer based on animal studies.